Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted by 11 to one that Lynparza (olaparib) should be approved for use alongside Johnson & Johnson’s Zytiga (abiraterone) and a ...

The new data comes from the KEYLYNK-001 study evaluating Keytruda (pembrolizumab) and chemotherapy followed by Lynparza (olaparib) maintenance therapy with or without bevacizumab in patients with ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

The first patient has been dosed in a phase 1b/2a trial (NCT06785636) of pocenbrodib, a CBP/p300 inhibitor, as a monotherapy and in combination with abiraterone acetate (Zytiga), olaparib (Lynparza), ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Chirag Shah, MD, MPH, an expert in gynecologic oncology, reviews the case of a 67-year-old woman with ovarian cancer and discusses factors to consider when selecting therapy including the recent ...